Part 1: High-Fidelity Donor Characterization and Successful Cell Therapy
TIL Therapy – Encouraging Results for Treating Metastatic Lung Cancer
Scientists at the H. Lee Moffitt Cancer Center in Florida are investigating the potential for using tumor infiltrating lymphocytes (TIL therapy) in the fight against metastatic lung cancer. [1] PD-1 immune checkpoint inhibitors and CAR T cell therapies are some of the most promising cancer treatments developed in recent years to help fight aggressive cancers. […]
Anti-PD1 Cancer Treatment – Excellos T Cells Aid Evaluation
Scientists at GSK in Waltham, Massachusetts, are using Excellos-sourced T cell starting material for their preclinical evaluation of an anti-PD1 antibody. Programmed Cell Death Protein-1 (PD-1) is a transmembrane protein recognized for its role in regulating T cell activity. PD-1 and its analogs are often called “checkpoint inhibitors” because they act as a checkpoint to […]
T Cell Immunotherapy – Excellos Cellular Material Helps Boost Development
T cell immunotherapy is a promising and relatively new field of medicine focused on tailoring a person’s own immune cells to fight disease more effectively. The field has enjoyed early success in the area of cancer immunotherapy, most notably the development of chimeric antigen receptor (CAR) T cells designed to express antigens that specifically target […]